Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial

Feng Huang(Chinese PLA General Hospital), Jieruo Gu(Sun Yat-sen University), Ping Zhu(Xijing Hospital), Chunde Bao(Renji Hospital), Jianhua Xu(First Affiliated Hospital of Anhui Medical University), Huji Xu(Second Military Medical University), Huaxiang Wu(Second Affiliated Hospital of Zhejiang University), Guochun Wang(China-Japan Friendship Hospital), Qun Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Nupun Andhivarothai(AbbVie (United States)), J. Anderson(AbbVie (United States)), Aileen L. Pangan(AbbVie (United States))
Annals of the Rheumatic Diseases
March 9, 2013
10.1136/annrheumdis-2012-202533
Cited by 121

Abstract

Related Papers

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al.|Arthritis & Rheumatism|2003|1.8k
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
Cédric Lukas, Robert Landewé, Joachim Sieper et al.|Annals of the Rheumatic Diseases|2008|1.1k
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Joseph M. Braun, Rosaline van den Berg, Xenofon Baraliakos et al.|Annals of the Rheumatic Diseases|2011|981
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
Désirée van der Heijde, Alan Kivitz, Michael Schiff et al.|Arthritis & Rheumatism|2006|877
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
Désirée van der Heijde, Ben A. C. Dijkmans, Piet Geusens et al.|Arthritis & Rheumatism|2005|860